Neurocrine Biosciences (NBIX) Change in Receivables (2016 - 2021)
Historic Change in Receivables for Neurocrine Biosciences (NBIX) over the last 12 years, with Q4 2021 value amounting to $21.7 million.
- Neurocrine Biosciences' Change in Receivables rose 1075000.0% to $21.7 million in Q4 2021 from the same period last year, while for Dec 2021 it was $28.4 million, marking a year-over-year decrease of 688.52%. This contributed to the annual value of $39.8 million for FY2024, which is 5543.11% down from last year.
- Latest data reveals that Neurocrine Biosciences reported Change in Receivables of $21.7 million as of Q4 2021, which was up 1075000.0% from $5.3 million recorded in Q3 2021.
- Neurocrine Biosciences' 5-year Change in Receivables high stood at $23.7 million for Q3 2017, and its period low was -$9.3 million during Q1 2021.
- Moreover, its 5-year median value for Change in Receivables was $9.6 million (2020), whereas its average is $9.2 million.
- Within the past 5 years, the most significant YoY rise in Neurocrine Biosciences' Change in Receivables was 1075000.0% (2021), while the steepest drop was 14208.14% (2021).
- Over the past 5 years, Neurocrine Biosciences' Change in Receivables (Quarter) stood at $1.3 million in 2017, then increased by 27.12% to $1.7 million in 2018, then soared by 579.09% to $11.3 million in 2019, then plummeted by 98.23% to $200000.0 in 2020, then surged by 10750.0% to $21.7 million in 2021.
- Its last three reported values are $21.7 million in Q4 2021, $5.3 million for Q3 2021, and $10.7 million during Q2 2021.